Biologics Spine Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook byJosh SandbergJanuary 8, 2026
Biologics Spine Top Stories Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months byTim AllenDecember 23, 2025
Regulatory Top Stories Bone Biologics Files Patent Application for Bone Regeneration Technology byJosh SandbergJune 27, 2025
Biologics Spine Top Stories Bone Biologics Appoints Phillip T. Meikle to its Board of Directors byJosh SandbergOctober 21, 2024
Financial Spine Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds byTim AllenAugust 2, 2024
Financial Bone Biologics Announces Closing of $2.0 Million Public Offering byJosh SandbergMarch 6, 2024
Financial Bone Biologics Announces Pricing of $2.0 Million Public Offering byJosh SandbergMarch 4, 2024
Biologics Spine Bone Biologics Reports Progress With NB1 Clinical Program byJosh SandbergMarch 1, 2024
